Related Experiment Video
Updated: Aug 29, 2026

Noninvasive Electrocardiography in the Perinatal Mouse
Published on: June 12, 2020
24-hour electrocardiogram before and during cisapride treatment in neonates and infants
Samuel A Zamora1, Dominique C Belli, Beat Friedli
1Gastroenterology Unit, Department of Pediatrics, University Hospital, Geneva, Switzerland. Samuel.Zamora@hcuge.ch
Insights
Cisapride prolonged the corrected Q-T interval (QTc) in preterm infants but did not cause significant arrhythmias. The drug lowered heart rates and reduced bradycardia in neonates with reflux.
Area of Science:
- Neonatal cardiology
- Pediatric pharmacology
Background:
- Gastroesophageal reflux disease is common in neonates, presenting as apparent life-threatening events, apneas, and bradycardias.
- Cisapride is used to treat gastrointestinal motility disorders in infants.
Purpose of the Study:
- To prospectively evaluate the effects of cisapride on heart rate and rhythm in term and preterm neonates and infants.
- To assess changes in corrected Q-T interval (QTc), Q-T dispersion (QTd), heart rate variability, and heart rhythm.
Main Methods:
- Prospective study involving standard and 24-hour ECG recordings in 31 neonates (14 term, 17 preterm) with gastroesophageal reflux disease.
- Measurements of QTc, QTd, heart rate, heart rate variability, and heart rhythm were taken before and after 3 days of cisapride treatment (0.8 mg/kg/day).
Main Results:
- Cisapride significantly increased QTc in preterm infants (408 to 433 ms).
- While QTc increased, QTd remained normal, and no clinically relevant arrhythmias were documented.
- Cisapride decreased peak and mean heart rates in all subjects, increased minimal heart rate in preterm infants, and reduced bradycardia episodes.
Conclusions:
- Cisapride can prolong ventricular action potential duration in preterm infants, but QTd and rhythm remained largely unaffected in this cohort.
- The drug demonstrates a beneficial effect by lowering heart rates and reducing bradycardia in infants with reflux.
- Further investigation into cisapride's cardiac effects in neonates is warranted, especially in preterm infants.
Abstract:
We studied prospectively the effects of cisapride on heart rate and rhythm using standard ECG and 24-hour ECG recordings in term and preterm neonates and infants. We studied subjects with gastroesophageal reflux disease (apparent life-threatening events, apneas, bradycardias) before and 3 days after starting cisapride (0.8 mg/kg/day in 4 doses). We performed standard ECGs for determination of corrected Q-T interval (QTc) and Q-T dispersion (QTd) and 24-hour ECG recordings for analysis of heart rate, heart rate variability, and heart rhythm. Fourteen term and 17 preterm subjects (gestational age range 28-36 weeks) were studied at a median chronological age of 29 (range 3-132) days. Cisapride significantly increased the QTc in preterm infants (before vs. after: 408 +/- 7 vs. 433 +/- 7 ms, p = 0.001). Two preterm and 1 term infant had a QTc >450 ms before cisapride. Four preterm (4/15 = 27%) and 2 term (2/13 = 15%) subjects had a QTc >450 ms on cisapride. After cisapride the QTd remained normal, and no relevant arrhythmias were documented on Holter recordings. Cisapride significantly decreased peak and mean heart rates of all study subjects without affecting the heart rate variability, while it increased the minimal heart rate of preterm infants only (before vs. after: 66 +/- 5 vs. 78 +/- 5 bpm, p = 0.02). The maximally measured R-R intervals (pauses) decreased after cisapride in preterm infants (before vs. after: 1.33 +/- 0.2 s vs. 1.05 +/- 0.2 s, p = 0.04). Although cisapride did cause a significant prolongation of the ventricular action potential duration in preterm infants, the QTd remained unaffected, and no clinically relevant arrhythmias were documented in this small sample. On the other hand, cisapride had a direct lowering effect on the maximal and mean heart rates of both term and preterm infants, while the drug increased the minimal heart rate and reduced the severity of bradycardia episodes in preterm infants.
Related Concept Videos
Electrocardiogram
Three major waveforms are present in a typical ECG recording: the P wave, the QRS complex, and the T...
Imaging Studies for Cardiovascular System V: CT
Cardiac Action Potential
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
Correlation between ECG and Cardiac Cycle
A cardiac action potential originates in the SA node and spreads throughout the atria and the AV node in approximately 0.03 seconds. This results in the P wave in an ECG and triggers atrial contraction. The action potential is then briefly slowed at the AV node, allowing the atria to contract and fill the ventricles with blood before...
Pulse rhythm
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac muscle...
Cardiac Catheterization IV: Nursing Management

